Photodynamic therapy with PhotoPoint photosensitiser MV6401, indium chloride methyl pyropheophorbide, achieves selective closure of rat corneal neovascularisation and rabbit choriocapillaris

British Journal of Ophthalmology

Volumn 89, Issue 1, 2005, Pages 113-119

  Ciulla, Thomas A ^a,b   Criswell, M H ^b   Snyder, W J ^c   Small IV, W ^c  

^a MIDWEST EYE INSTITUTE   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Miravant Medical Technologies   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPTANOL; INDIUM CHLORIDE; INDIUM CHLORIDE METHYL PYROPHEOPHORBIDE; MV 6401; PHEOPHORBIDE; PHOTOSENSITIZING AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOROID CAPILLARY LAYER; CONTROLLED STUDY; CORNEA NEOVASCULARIZATION; DIODE LASER; DOSE RESPONSE; DRUG ACTIVATION; DRUG EFFICACY; DRUG POTENCY; DRUG SELECTIVITY; FEMALE; FLUORESCENCE ANGIOGRAPHY; HISTOLOGY; LIGHT INTENSITY; MALE; NONHUMAN; OPHTHALMOSCOPY; PHOTODYNAMIC THERAPY; PHOTOGRAPHY; PRIORITY JOURNAL; RABBIT; RAT;

ANIMALS; CAPILLARIES; CHOROID; CORNEAL NEOVASCULARIZATION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUORESCEIN ANGIOGRAPHY; INDIUM; INJECTIONS, INTRAVENOUS; MALE; ORGANOMETALLIC COMPOUNDS; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; RABBITS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 11144275177     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.2004.043075     Document Type: Article

References (13)

1. Payne JT, McCaw DL, Casteel SW, et al. Pharmacokinetics of pyropheophorbide-a-hexyl ether in the dog. Lasers Surg Med 1996;18:406-9.
2. Bellnier DA, Henderson BW, Pandey RK, et al. Murine pharmacokinetics and antitumor efficacy of the photodynamic sensitizer 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a. J Photochem Photobiol B 1993;20:55-61.
3. Pandey RK, Sumlin AB, Constantine S, et al. Alkyl ether analogs of chlorophyll-a derivatives: Part 1. Synthesis, photophysical properties and photodynamic efficacy. Photochem Photobiol 1996;64:194-204.
4. Primbs GB, Casey R, Wamser K, et al. Photodynamic therapy for corneal neovascularization. Ophthalmic Surg Lasers 1998;29:832-8.
5. Gohto Y, Obana A, Kaneda K, et al. Photodynamic effect of a new photosensitizer ATX-S10 on corneal neovascularization. Exp Eye Res 1998;67:313-22.
6. Moshfeghi DM, Peyman GA, Moshfeghi AA, et al. Ocular vascular thrombosis following tin ethyl etiopurpurin (SnET2) photodynamic therapy: time dependencies. Ophthalmic Surg Lasers 1998;29:663-8.
7. Peyman GA, Moshfeghi DM, Moshfeghi A, et al. Photodynamic therapy for choriocapillaris using tin ethyl etiopurpurin (SnET2). Ophthalmic Surg Lasers 1997;28:409-17.
8. Costa RA, Farah ME, Freymuller E, et al. Choriocapillaris photodynamic therapy using indocyanine green. Am J Ophthalmol 2001;132:557-65.
9. Huang A, Watson B, Hernandez E, et al. Induction of conjunctival transdifferentiation on vascularized corneas by photothrombotic occlusion of corneal neovascularization. Ophthalmology 1988;95:228-35.
10. Tseng S, Hirst L, Farazdaghi M, et al. Goblet cell density and vascularization during conjunctival transdifferentiation. Invest Ophthalmol Vis Sci 1984;25:1168-76.
11. Bressler NM. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-verteporfin in photodynamic therapy report 2. Am J Ophthalmol 2002;133:168-9.
12. Blumenkranz MS, Bressler NM, Bressler SB, et al. Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: three-year results of an open-label extension of 2 randomized clinical trials-TAP Report no 5. Arch Ophthalmol 2002;120:1307-14.
13. Anon. Guidelines for using verteporfin (Visudyne) in photodynamic therapy to treat choroidal neovascularization due to age-related macular degeneration and other causes. Retina 2002;22:6-18.